This company listing is no longer active
2191 Stock Overview
tella, Inc. researches and develops regenerative and cell medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
tella, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2.00 |
| 52 Week High | JP¥227.00 |
| 52 Week Low | JP¥2.00 |
| Beta | 1.85 |
| 1 Month Change | -97.96% |
| 3 Month Change | -97.47% |
| 1 Year Change | -98.99% |
| 3 Year Change | -98.97% |
| 5 Year Change | -99.64% |
| Change since IPO | -99.33% |
Recent News & Updates
Shareholder Returns
| 2191 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -75.0% | -0.4% | -2.6% |
| 1Y | -99.0% | -33.6% | 28.4% |
Return vs Industry: 2191 underperformed the JP Life Sciences industry which returned 13.5% over the past year.
Return vs Market: 2191 underperformed the JP Market which returned 0.6% over the past year.
Price Volatility
| 2191 volatility | |
|---|---|
| 2191 Average Weekly Movement | 33.1% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 2191's share price has been volatile over the past 3 months.
Volatility Over Time: 2191's weekly volatility has increased from 19% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 30 | Yuichiro Yazaki | www.tella.jp |
tella, Inc. researches and develops regenerative and cell medicines. The company offers techniques and operational knowhow associated with dendritic cell vaccine therapy to affiliated medical institutions for the treatment of cancer. It is also involved in the provision of consultation services on the establishment and maintenance of cell processing centers, and on introduction of management systems for cell cultivation; and lease of standard operating procedure and regular checks on manufacturing operation management and training of cell cultivation technicians.
tella, Inc. Fundamentals Summary
| 2191 fundamental statistics | |
|---|---|
| Market cap | JP¥50.65m |
| Earnings (TTM) | -JP¥898.00m |
| Revenue (TTM) | JP¥89.00m |
0.6x
P/S Ratio-0.1x
P/E RatioIs 2191 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2191 income statement (TTM) | |
|---|---|
| Revenue | JP¥89.00m |
| Cost of Revenue | JP¥193.00m |
| Gross Profit | -JP¥104.00m |
| Other Expenses | JP¥794.00m |
| Earnings | -JP¥898.00m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -35.46 |
| Gross Margin | -116.85% |
| Net Profit Margin | -1,008.99% |
| Debt/Equity Ratio | 0% |
How did 2191 perform over the long term?
See historical performance and comparison